Foghorn Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $7,808 | $6,888 | $5,050 | $5,769 |
Gross Profit | 7,108 | 6,088 | 4,215 | 4,917 |
EBITDA | -23,852 | -23,443 | -27,359 | -24,606 |
EBIT | -24,585 | -24,243 | -28,194 | -25,458 |
Net Income | -19,122 | -22,979 | -25,016 | -24,106 |
Net Change In Cash | 7,808 | 6,888 | 5,050 | 5,769 |
Free Cash Flow | -21,314 | -25,554 | -29,446 | -27,578 |
Cash | 57,678 | 138,947 | 79,253 | 80,336 |
Basic Shares | 62,602 | 51,580 | 42,428 | 42,282 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $34,155 | $19,228 | $1,319 | $430 |
Gross Profit | -75,534 | 19,208 | -6,196 | -57,285 |
EBITDA | -104,455 | -113,816 | -96,187 | -66,494 |
EBIT | -107,906 | -117,137 | -103,702 | -72,022 |
Net Income | -98,426 | -108,873 | -103,226 | -69,779 |
Net Change In Cash | 34,155 | 19,228 | 1,319 | 430 |
Cost of Revenue | -48,947 | 8,341 | 77,273 | |
Free Cash Flow | -119,330 | 192,402 | -53,563 | -47,469 |
Cash | 80,336 | 345,798 | 101,136 | 92,795 |
Basic Shares | 41,974 | 41,591 | 37,171 | 36,790 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.31 |
2024-06-30 | -$0.45 |
2024-03-31 | -$0.59 |
2023-12-31 | -$0.57 |
